

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3906002
<b>Application Number:</b>	10787442
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8214
<b>Title of Invention:</b>	Cytokine zalpha11 ligand fusion proteins
<b>First Named Inventor/Applicant Name:</b>	Julia E. Novak
<b>Customer Number:</b>	10117
<b>Filer:</b>	Deborah A. Sawislak./Kim Goplen
<b>Filer Authorized By:</b>	Deborah A. Sawislak.
<b>Attorney Docket Number:</b>	99-16D3
<b>Receipt Date:</b>	08-SEP-2008
<b>Filing Date:</b>	26-FEB-2004
<b>Time Stamp:</b>	17:37:22
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1225
RAM confirmation Number	3130
Deposit Account	260290
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

**File Listing:**

<b>Document Number</b>	<b>Document Description</b>	<b>File Name</b>	<b>File Size(Bytes)/Message Digest</b>	<b>Multi Part /.zip</b>	<b>Pages (if appl.)</b>
1	Request for Continued Examination (RCE)	99-16D3RCE.pdf	31433 6c827f4252bad846ac5e6cc1274e833b5d3 96e81	no	1

**Warnings:**

This is not a USPTO supplied RCE SB30 form.

**Information:**

2	Extension of Time	99-16D3RCExtendtime.pdf	26353 5b9286720db86dd91fd023f689967b7219 872fe	no	1
---	-------------------	-------------------------	--	----	---

**Warnings:**
**Information:**

3	Letter Express Abandonment of the application	99-16C2expressabandon.pdf	19188 658cc104f3b3cefc53e31c9a46b8df5df8e98 7e4	no	1
---	---	---------------------------	---	----	---

**Warnings:**
**Information:**

4		99-16D3AAF.pdf	365038 3418e5da4b18874e0be74ff3c5e29c90eb6 8d552	yes	11
---	--	----------------	--	-----	----

**Multipart Description/PDF files in .zip description**

	<b>Document Description</b>	<b>Start</b>	<b>End</b>
	Amendment Submitted/Entered with Filing of CPA/RCE	1	1
	Claims	2	2
	Applicant Arguments/Remarks Made in an Amendment	3	11

**Warnings:**
**Information:**

5	Fee Worksheet (PTO-06)	fee-info.pdf	32033 150d5b58c096f2f5312af555e16ea202b840 0b58	no	2
---	------------------------	--------------	---	----	---

**Warnings:**
**Information:**

<b>Total Files Size (in bytes):</b>	474045
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.